Document is current
Any future updates will be listed below
-
Authors
Piastra, Valentina
Ganci, Federica
Sacconi, Andrea
Pranteda, Angelina
Allegretti, Matteo
Bernardini, Roberta
Serra, Martina
Lupo, Barbara
Dell’Aquila, Emanuela
Ferretti, Gianluigi
Pescarmona, Edoardo
Bartolazzi, Armando
Blandino, Giovanni
Trusolino, Livio
Bossi, Gianluca http://orcid.org/0000-0002-2947-1063
- License Information
-
More Information
Article History
Received: 22 March 2024
Accepted: 4 August 2024
First Online: 20 August 2024
Declarations
:
: The aims of this study, which involved the use of CRC PDOs provided by Prof. Trusolino, fall within the institutional study "Prospective study for the determination of the molecular profile of resistance to antineoplastic treatments"—PROFILING – approved by the IRCCS Ethics Committee of Candiolo with authorization v. 11.0 dated 13.07.2022.All studies involving animals were executed following the EU Directive 2010/63/EU in compliance with institutional guidelines, regulations and authorizations by appropriate institutional review boards (141/2017-PR dated 02/13/2017, and 339/2023-PR dated 04/14/2023). The tumor size, which the maximal tumor burden authorized of 2.0cm<sup>3</sup> was never exceeded in all experiments addressed.
: Not applicable.
: All authors disclose any competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
